Baxter International (BAX) Cost of Revenue (2009 - 2026)

Baxter International (BAX) has reported Cost of Revenue for 18 consecutive years, with $1.9 billion the latest figure, recorded in Q2 2026.

• In Q2 2026, Cost of Revenue rose 5.99% year-over-year to $1.9 billion; the TTM figure through Jun 2026 stood at $7.3 billion (up 3.95% YoY), while the FY2025 annual figure was $7.9 billion, up 18.24% from the prior year.
• Cost of Revenue advanced to $1.9 billion in Q2 2026 per BAX's latest filing, from $1.8 billion in the prior quarter.
• Across five years, Cost of Revenue topped out at $2.6 billion in Q2 2023 and bottomed at -$1.2 billion in Q4 2023.
• Historically, Cost of Revenue has averaged $1.7 billion across 5 years, with a median of $1.9 billion in 2025.
• Annual changes were most pronounced in 2022 — Cost of Revenue tumbled 131.0% — and 2024, when it soared 247.65%.
• Baxter International's Cost of Revenue stood at -$575.0 million in 2022, then slumped by 111.3% to -$1.2 billion in 2023, then jumped by 247.65% to $1.8 billion in 2024, then rose by 1.39% to $1.8 billion in 2025, then grew by 5.99% to $1.9 billion in 2026.
• Business Quant data shows BAX's Cost of Revenue at $1.9 billion in Q2 2026, $1.8 billion in Q1 2026, and $1.8 billion in Q2 2025.